Ionis Pharmaceuticals Gelecekteki Büyüme
Future kriter kontrolleri 6/6
Ionis Pharmaceuticals kazanç ve gelirin sırasıyla yıllık 68% ve 28.2% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 66.6% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 48.3% olacağı tahmin edilmektedir.
Anahtar bilgiler
68.0%
Kazanç büyüme oranı
66.62%
EPS büyüme oranı
| Biotechs kazanç büyümesi | 28.8% |
| Gelir büyüme oranı | 28.2% |
| Gelecekteki özkaynak getirisi | 48.26% |
| Analist kapsamı | Good |
| Son güncelleme | 08 Sep 2026 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Seeking Alpha • Sep 04
Ionis: Downgrading To Sell After A Series Of Unfortunate Events
Summary Ionis Pharmaceuticals, Inc. faces significant setbacks after initial optimism, with shares dropping sharply from 52-week highs amid clinical and competitive disappointments. IONS’ blockbuster ambitions for WAINUA and TRYNGOLZA have diminished; WAINUA is now a niche hATTR-PN therapy, and TRYNGOLZA faces direct competition from Arrowhead’s plozasiran. Recent failed Phase 2/3 trials with partners AstraZeneca, Roche, and Biogen have eroded near-term growth prospects and market confidence. Despite a $2B cash position, IONS's path to cash flow breakeven in 2028 is now clouded by pipeline setbacks and intensifying competition. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Sep 03
IONS: Trial Setbacks And 2026 Launch Milestones Will Shape Balanced Outlook
Ionis Pharmaceuticals' updated analyst price target has shifted from about $80 to $61 as analysts weigh recent trial setbacks and competitive readthroughs against the company’s marketed products, late stage pipeline, and ongoing launch and regulatory milestones. Analyst Commentary Recent Street research on Ionis Pharmaceuticals shows a clear split between bullish and cautious voices.
Anlatı Güncellemesi • Aug 20
IONS: Severe Hypertriglyceridemia Franchise Will Define 2026 Risk Reward Profile
Ionis Pharmaceuticals' fair value estimate has been trimmed from $92.00 to $88.00 as analysts weigh a higher discount rate against updated revenue growth and margin assumptions following recent shifts in price targets and mixed trial outcomes. Analyst Commentary Recent Street research on Ionis Pharmaceuticals reflects a split view.
Anlatı Güncellemesi • Aug 06
IONS: sHTG Launch And Late Stage Pipeline Will Support Future Earnings Power
Ionis Pharmaceuticals' updated analyst price target is now $114.18, with analysts pointing to revised expectations for higher revenue growth and profit margins, offset by a lower future P/E assumption and a slightly higher discount rate, following recent mixed trial outcomes and ongoing enthusiasm around the Tryngolza and sHTG opportunity. Analyst Commentary Recent Street research on Ionis Pharmaceuticals points to a split view.Anlatı Güncellemesi • Jul 23
IONS: Tryngolza Approval And Rare Disease Pipeline Will Reshape 2026 Risk Reward Profile
Ionis Pharmaceuticals' fair value estimate has been reset from $104.86 to $92.00, as analysts incorporate the Phase 3 eplontersen cardiomyopathy miss, related trims to revenue growth and profit margin assumptions, and a higher projected future P/E. These factors are all reflected in a wave of reduced price targets across the Street.Anlatı Güncellemesi • Jul 09
IONS: Severe Triglyceride Label Win Will Reshape 2026 Risk Reward Profile
Analysts have raised the Ionis Pharmaceuticals fair value estimate by about $3.94 to $104.86, citing updated price targets following the FDA approval of Tryngolza, as well as increased confidence in the company’s proprietary and partnered pipeline. Analyst Commentary Recent research on Ionis Pharmaceuticals clusters around the FDA approval of Tryngolza and its implications for valuation, execution risk and long term growth potential across the company’s proprietary and partnered pipeline.Anlatı Güncellemesi • Jun 25
IONS: FDA Approvals And 2026 Readouts Will Test Balanced Expectations
The analyst price target for Ionis Pharmaceuticals has been raised from $62.78 to $79.71, with analysts citing the FDA approval of Tryngolza and updated assumptions for revenue growth, profit margin, and future P/E as key drivers of the change. Analyst Commentary Recent Street research on Ionis Pharmaceuticals centers on the FDA approval of Tryngolza and how this new product feeds into long term revenue, margin, and P/E assumptions.Analiz Makalesi • Jun 22
Ionis Pharmaceuticals (IONS) Stock Could Be 26.6% Undervalued After New Olezarsen Data
Ionis Pharmaceuticals (IONS) recently shared new long-term data on its RNA therapy olezarsen for severe hypertriglyceridemia, highlighting sustained effects on liver fat and a favorable safety profile in an ongoing extension study. See our latest analysis for Ionis Pharmaceuticals. Ionis Pharmaceuticals’ share price is US$74.12, with short term moves roughly flat as the 7 day share price return of 1.15% and 30 day share price return, down 1.91%, contrast with a much stronger 1 year total...Anlatı Güncellemesi • Jun 11
IONS: Priority Review In Severe Triglycerides Will Drive 2026 Risk Reward Repricing
Analysts have lifted their average price target on Ionis Pharmaceuticals toward $115, reflecting renewed focus on the $3.5b-plus Tryngloza opportunity in severe hypertriglyceridemia and upcoming partnered Phase 3 readouts in 2026, while leaving the modeled fair value at about $100.92 as the discount rate and margin assumptions are fine tuned. Analyst Commentary Street research around Ionis Pharmaceuticals has centered on how much value to ascribe to Tryngloza and the broader pipeline, with recent work fine tuning price targets and risk assumptions rather than radically changing the fundamental narrative.Anlatı Güncellemesi • May 28
IONS: Priority Review In Severe Triglycerides Will Reshape 2026 Risk Reward Profile
Ionis Pharmaceuticals' fair value estimate has moved from $96.73 to $100.92 as analysts factor in higher assumed revenue growth, a stronger profit margin profile, and a lower future P/E multiple, supported by a wave of higher price targets and fresh Buy initiations that highlight the potential of Tryngloza and upcoming partnered Phase 3 readouts. Analyst Commentary Recent Street research around Ionis Pharmaceuticals has been active, with multiple firms adjusting price targets and launching new coverage.Analiz Makalesi • May 11
Need To Know: Analysts Are Much More Bullish On Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Revenues
Shareholders in Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) may be thrilled to learn that the analysts have just...Anlatı Güncellemesi • May 02
IONS: Priority FDA Reviews In 2026 Will Support Stronger Earnings Power
Analysts have nudged the Ionis Pharmaceuticals fair value estimate higher to $130 from $120, citing a series of price target increases across the Street and updated assumptions around growth, profitability, and future P/E levels. Analyst Commentary Recent Street research around Ionis Pharmaceuticals has leaned constructive, with a cluster of bullish analysts lifting price targets and reinforcing a positive view on execution and long term growth potential, even as one firm trimmed its target.Analiz Makalesi • May 01
Earnings Beat: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) just released its first-quarter report and things are looking bullish. The...Anlatı Güncellemesi • Apr 18
IONS: Priority Review For Severe Triglycerides Will Reframe 2026 Risk Reward Profile
Analysts have raised their fair value estimate for Ionis Pharmaceuticals by about $3 to $96.73, citing updated assumptions for higher revenue growth, a wider profit margin, and a lower future P/E multiple, along with a series of recent price target increases and positive ratings resets from major firms. Analyst Commentary Recent research updates on Ionis Pharmaceuticals have leaned constructive, with several firms lifting price targets and reiterating positive ratings following the latest quarterly results and pipeline updates.Anlatı Güncellemesi • Apr 04
IONS: Priority FDA Reviews In 2026 Will Support Stronger Profitability Profile
Analysts have lifted the Ionis Pharmaceuticals fair value estimate by $3.24 to $120.00, as they factor in updated assumptions around revenue growth, profit margins, and future P/E multiples following recent price target increases across the Street. Analyst Commentary Bullish analysts have been lifting Ionis Pharmaceuticals price targets across several research updates, which feeds directly into the higher fair value estimate.Anlatı Güncellemesi • Mar 20
IONS: Priority Review For Severe Triglycerides Will Shape 2026 Outlook
Ionis Pharmaceuticals' updated analyst price target moves higher to $93.90 from $90.67. Analysts point to recent target hikes, Q4 results commentary and upcoming 2026 catalysts as key supports for this shift.Anlatı Güncellemesi • Mar 06
IONS: 2026 Regulatory Event Risk Will Test Elevated Expectations
Ionis Pharmaceuticals' fair value estimate has been raised from $43.00 to about $62.78 as analysts factor in higher long term revenue growth assumptions, updated margin expectations, and recent price target increases following Q4 results, olezarsen progress, and a busy 2026 catalyst calendar. Analyst Commentary Recent Street research on Ionis Pharmaceuticals points to a more constructive stance on the story overall, but there are still threads of caution that matter if you are thinking about risk, valuation, and execution over the next couple of years.Anlatı Güncellemesi • Feb 19
IONS: Late-Stage RNA Programs Will Support Stronger Future Profitability Profile
Analysts have lifted their price target on Ionis Pharmaceuticals by $10, citing updated expectations around revenue growth, profit margins and a lower future P/E assumption, as reflected in recent research from firms covering the stock. Analyst Commentary Recent Street research points to a generally constructive tone on Ionis Pharmaceuticals, with bullish analysts highlighting both valuation and execution angles in their updated work.Anlatı Güncellemesi • Feb 05
IONS: Triglyceride Market Shift And SHTG Launch Progress Will Shape Outlook
Analysts nudged their fair value target for Ionis Pharmaceuticals slightly higher to about US$90.67 from roughly US$90.63, citing updated assumptions around discount rates, revenue growth, profit margins and a higher future P/E, along with recent Street research that highlights evolving expectations for the triglyceride lowering market where Ionis and Arrowhead both participate. Analyst Commentary Bullish Takeaways Bullish analysts view the refreshed fair value near US$90.67 as consistent with a company that could justify a higher future P/E, reflecting confidence in execution rather than only near term trading sentiment.Anlatı Güncellemesi • Jan 22
IONS: Upcoming SHTG Data And Launch Execution Will Support Bullish Thesis
Analysts have lifted their fair value estimate for Ionis Pharmaceuticals to about US$90.63 from roughly US$89.40, citing updated models that reflect recent Q3 performance, higher assumed revenue growth and profit margins, as well as a lower future P/E. This comes alongside Street price target increases to US$94 and US$99 following Tryngolza driven strength and expectations around upcoming SHTG data.Anlatı Güncellemesi • Jan 08
IONS: Late-Stage Data And New Launches Will Shape Balanced Risk Profile
Analysts nudged their fair value estimate for Ionis Pharmaceuticals higher from about $85.95 to roughly $89.40. They pointed to updated models that reflect recent price target increases, added expectations for Tryngolza in FCS and severe hypertriglyceridemia, and revised long term margin and P/E assumptions.Anlatı Güncellemesi • Dec 24
IONS: Late-Stage RNA Pipeline Will Drive Stronger Profitability Outlook
Analysts have raised their fair value estimate for Ionis Pharmaceuticals from approximately $96 to about $117 per share, citing strong Q3 outperformance led by Tryngolza, expanded peak sales assumptions for key lipid programs, and growing confidence in the late-stage pipeline and path to profitability. Analyst Commentary Bullish analysts are increasingly constructive on Ionis Pharmaceuticals following a series of positive catalysts, including strong Q3 performance from Tryngolza, encouraging late-stage data, and visible progress toward breakeven and long term profitability.Anlatı Güncellemesi • Dec 10
IONS: Late-Stage Data And Multiple Launches Will Shape Balanced Long-Term Outlook
Analysts have modestly raised their fair value estimate for Ionis Pharmaceuticals to approximately $86 per share. This reflects higher peak sales assumptions for Tryngolza and other late stage programs, a slightly richer pricing outlook in severe hypertriglyceridemia, and growing confidence in the company reaching multi billion dollar revenue and profitability in the early 2030s.Anlatı Güncellemesi • Nov 26
IONS: Upcoming Late-Stage Data and Recent Regulatory Progress Will Shape Balanced Outlook
Ionis Pharmaceuticals’ analyst price target has been raised from approximately $82 to $85 per share. This reflects analyst optimism following strong Phase 3 trial results, upward sales guidance, and an improved clinical and commercial outlook across multiple pipeline programs.Anlatı Güncellemesi • Nov 05
IONS: Continued Clinical Success Will Drive Meaningful Upside After Recent Regulatory Wins
The consensus analyst price target for Ionis Pharmaceuticals has increased significantly, rising from approximately $77 to over $82. Analysts cite robust clinical trial results, new product milestones, and a strengthened commercial outlook as key drivers behind their upward revisions.Analiz Makalesi • Nov 01
Earnings Update: Here's Why Analysts Just Lifted Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Price Target To US$81.91
Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) defied analyst predictions to release its third-quarter results, which were...Anlatı Güncellemesi • Oct 22
Analyst Commentary Highlights Ionis Pharmaceuticals’ Upward Price Target and Valuation Amid Key Clinical Wins
Ionis Pharmaceuticals’ analyst price target has been raised from approximately $73 to $77. Analysts cite stronger-than-expected clinical and commercial progress across key late-stage programs, as well as expanded opportunities in rare disease markets.Anlatı Güncellemesi • Oct 08
Pipeline Milestones And Expanding Patient Pools Will Broaden Market Reach
Ionis Pharmaceuticals’ analyst price target has been raised from approximately $69.48 to $73.03, as analysts cite strong Phase 3 results across multiple programs and expanded opportunities in ultra-rare indications, which support increased sales and profit expectations. Analyst Commentary Recent analyst updates on Ionis Pharmaceuticals reveal a nuanced outlook as the company benefits from significant clinical milestones and expanding commercial prospects, but also faces some areas of uncertainty.Anlatı Güncellemesi • Sep 23
Pipeline Milestones And Expanding Patient Pools Will Broaden Market Reach
Analysts increased their price targets for Ionis Pharmaceuticals following "groundbreaking" Phase 3 data for olezarsen, blockbuster expectations, and a major regulatory win for Dawnzera, resulting in a modest consensus target rise from $68.35 to $69.48. Analyst Commentary Bullish analysts significantly raised price targets after Phase 3 trial data for olezarsen/Tryngolza in severe hypertriglyceridemia showed "groundbreaking" or "highly statistically significant" triglyceride reductions and, notably, the first proven benefit in reducing acute pancreatitis.Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2028 | 1,947 | 37 | -79 | 141 | 16 |
| 12/31/2027 | 1,382 | -314 | -336 | -192 | 23 |
| 12/31/2026 | 913 | -584 | -524 | -442 | 23 |
| 6/30/2026 | 874 | -565 | -568 | -496 | N/A |
| 3/31/2026 | 1,058 | -327 | -978 | -911 | N/A |
| 12/31/2025 | 944 | -381 | -326 | -269 | N/A |
| 9/30/2025 | 967 | -256 | -309 | -247 | N/A |
| 6/30/2025 | 944 | -268 | -282 | -231 | N/A |
| 3/31/2025 | 717 | -458 | -560 | -502 | N/A |
| 12/31/2024 | 705 | -454 | -551 | -501 | N/A |
| 9/30/2024 | 803 | -359 | -374 | -352 | N/A |
| 6/30/2024 | 813 | -366 | -375 | -346 | N/A |
| 3/31/2024 | 777 | -385 | -345 | -323 | N/A |
| 12/31/2023 | 788 | -366 | -336 | -308 | N/A |
| 9/30/2023 | 615 | -409 | -574 | -541 | N/A |
| 6/30/2023 | 631 | -309 | -493 | -456 | N/A |
| 3/31/2023 | 576 | -329 | -405 | -377 | N/A |
| 12/31/2022 | 587 | -270 | -294 | -274 | N/A |
| 9/30/2022 | 875 | 7 | 110 | 130 | N/A |
| 6/30/2022 | 849 | -28 | 82 | 98 | N/A |
| 3/31/2022 | 841 | -4 | 35 | 54 | N/A |
| 12/31/2021 | 810 | -29 | 13 | 31 | N/A |
| 9/30/2021 | 661 | -608 | -96 | -75 | N/A |
| 6/30/2021 | 688 | -550 | -59 | -30 | N/A |
| 3/31/2021 | 708 | -495 | -45 | -11 | N/A |
| 12/31/2020 | 729 | -444 | -5 | 36 | N/A |
| 9/30/2020 | 933 | 94 | 173 | 216 | N/A |
| 6/30/2020 | 940 | 145 | 165 | 213 | N/A |
| 3/31/2020 | 959 | 169 | N/A | 230 | N/A |
| 12/31/2019 | 1,123 | 281 | N/A | 346 | N/A |
| 9/30/2019 | 821 | 433 | N/A | 183 | N/A |
| 6/30/2019 | 799 | 402 | N/A | 170 | N/A |
| 3/31/2019 | 752 | 366 | N/A | 697 | N/A |
| 12/31/2018 | 600 | 277 | N/A | 603 | N/A |
| 9/30/2018 | 575 | -41 | N/A | 508 | N/A |
| 6/30/2018 | 548 | -38 | N/A | 563 | N/A |
| 3/31/2018 | 543 | 9 | N/A | 65 | N/A |
| 12/31/2017 | 514 | 19 | N/A | 174 | N/A |
| 9/30/2017 | 507 | 42 | N/A | 127 | N/A |
| 6/30/2017 | 499 | 52 | N/A | 122 | N/A |
| 3/31/2017 | 426 | -15 | N/A | 86 | N/A |
| 12/31/2016 | 373 | -60 | N/A | -112 | N/A |
| 9/30/2016 | 238 | -184 | N/A | -123 | N/A |
| 6/30/2016 | 176 | -227 | N/A | -111 | N/A |
| 3/31/2016 | 258 | -134 | N/A | -12 | N/A |
| 12/31/2015 | 284 | -88 | N/A | 21 | N/A |
| 9/30/2015 | 317 | 14 | N/A | 129 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: IONS önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 3.7% ) daha hızlı bir büyüme olarak değerlendiriliyor.
Kazançlar ve Piyasa: IONS önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.
Yüksek Büyüme Kazançları: IONS önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.
Gelir ve Pazar: IONS şirketinin gelirinin (yıllık 28.2% ) US pazarından (yıllık 13.5% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Geliri: IONS şirketinin gelirinin (yıllık 28.2% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: IONS 'nin Özsermaye Getirisi'nin 3 yıl içinde çok yüksek olması tahmin ediliyor ( 48.3 %).
Büyüyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/09/11 02:51 |
| Gün Sonu Hisse Fiyatı | 2026/09/11 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Ionis Pharmaceuticals, Inc. 43 Bu analistlerden 23, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Eliana Merle | Barclays |
| James Birchenough | Barclays |
| Huidong Wang | Barclays |